Effect of cyclodextrin concentration on the oral bioavailability of danazol and cinnarizine in rats

René Holm; Niels Erik Olesen; Rune A. Hartvig; Erling B. Jørgensen; Dorrit Bjerg Larsen; Peter Westh

doi:10.1016/j.ejpb.2016.01.007

Effect of cyclodextrin concentration on the oral bioavailability of danazol and cinnarizine in rats

René Holm, Niels Erik Olesen, Rune A. Hartvig, Erling B. Jørgensen, Dorrit Bjerg Larsen, Peter Westh

In: European Journal of Pharmaceutics and Biopharmaceutics · 2016 · vol. 101 , pp. 9–14 · doi:10.1016/j.ejpb.2016.01.007 · PMID:26776271 · W2284564108

article OA: closed CC0 ⤵ 3 in-corpus citations

Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".

View at publisher → View on OpenAlex View on PubMed

My notes (saved in your browser only)

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (35)

A Study of the Complexation Between Danazol and Hydrophilic Cyclodextrin Derivatives via openalex
Characterization and bioavailability of danazol-hydroxypropyl β-cyclodextrin coprecipitates via openalex
Hygroscopicity, phase solubility and dissolution of various substituted sulfobutylether β-cyclodextrins (SBE) and danazol–SBE inclusion complexes via openalex
Lipid-based Formulations for Danazol Containing a Digestible Surfactant, Labrafil M2125CS: In Vivo Bioavailability and Dynamic In Vitro Lipolysis via openalex
Optimization of PEGylated nanoemulsions for improved pharmacokinetics of BCS class II compounds via openalex
Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs via openalex
doi:10.1021/cr970025p via openalex
W2148040442 via openalex
doi:10.1007/s10847-010-9831-3 via openalex
W2370566290 via openalex
W6679729425 via openalex
W6694945155 via openalex
doi:10.1002/jps.24678 via openalex
doi:10.1177/0192623307310945 via openalex
doi:10.1016/0223-5234(87)90280-7 via openalex
doi:10.1021/js950534b via openalex
doi:10.1016/j.ijpharm.2007.04.029 via openalex
doi:10.1016/j.jconrel.2004.06.013 via openalex
doi:10.1111/j.2042-7158.2011.01279.x via openalex
doi:10.1002/jps.2600840306 via openalex
doi:10.1016/j.ijpharm.2010.07.046 via openalex
doi:10.1002/jps.22226 via openalex
doi:10.1002/jps.24496 via openalex
doi:10.1016/j.xphs.2015.10.027 via openalex
doi:10.1007/s10847-012-0165-1 via openalex
doi:10.1002/jps.23384 via openalex
doi:10.1023/a:1016047215907 via openalex
doi:10.1016/j.ejps.2015.05.024 via openalex
doi:10.1002/jps.22033 via openalex
doi:10.1021/js960075u via openalex
doi:10.1016/s0169-409x(98)00052-0 via openalex
doi:10.1371/journal.pone.0068237 via openalex
doi:10.1002/jps.20198 via openalex
doi:10.1002/jps.20534 via openalex
doi:10.1023/a:1023037016997 via openalex

Cited by (3)

Source provenance

openalex: last seen: 2026-05-13T20:07:10.637958+00:00

License: CC0 · commercial use OK

[1] A Study of the Complexation Between Danazol and Hydrophilic Cyclodextrin Derivatives via openalex

[2] Characterization and bioavailability of danazol-hydroxypropyl β-cyclodextrin coprecipitates via openalex

[3] Hygroscopicity, phase solubility and dissolution of various substituted sulfobutylether β-cyclodextrins (SBE) and danazol–SBE inclusion complexes via openalex

[4] Lipid-based Formulations for Danazol Containing a Digestible Surfactant, Labrafil M2125CS: In Vivo Bioavailability and Dynamic In Vitro Lipolysis via openalex

[5] Optimization of PEGylated nanoemulsions for improved pharmacokinetics of BCS class II compounds via openalex

[6] Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs via openalex

[7] doi:10.1021/cr970025p via openalex

[8] W2148040442 via openalex

[9] doi:10.1007/s10847-010-9831-3 via openalex

[10] W2370566290 via openalex

[11] W6679729425 via openalex

[12] W6694945155 via openalex

[13] doi:10.1002/jps.24678 via openalex

[14] doi:10.1177/0192623307310945 via openalex

[15] doi:10.1016/0223-5234(87)90280-7 via openalex

[16] doi:10.1021/js950534b via openalex

[17] doi:10.1016/j.ijpharm.2007.04.029 via openalex

[18] doi:10.1016/j.jconrel.2004.06.013 via openalex

[19] doi:10.1111/j.2042-7158.2011.01279.x via openalex

[20] doi:10.1002/jps.2600840306 via openalex

[21] doi:10.1016/j.ijpharm.2010.07.046 via openalex

[22] doi:10.1002/jps.22226 via openalex

[23] doi:10.1002/jps.24496 via openalex

[24] doi:10.1016/j.xphs.2015.10.027 via openalex

[25] doi:10.1007/s10847-012-0165-1 via openalex

[26] doi:10.1002/jps.23384 via openalex

[27] doi:10.1023/a:1016047215907 via openalex

[28] doi:10.1016/j.ejps.2015.05.024 via openalex

[29] doi:10.1002/jps.22033 via openalex

[30] doi:10.1021/js960075u via openalex

[31] doi:10.1016/s0169-409x(98)00052-0 via openalex

[32] doi:10.1371/journal.pone.0068237 via openalex

[33] doi:10.1002/jps.20198 via openalex

[34] doi:10.1002/jps.20534 via openalex

[35] doi:10.1023/a:1023037016997 via openalex